Does partial blockade of dopamine D2 receptors with Amisulpride cause anhedonia? An experimental study in healthy volunteers

Berg, Max; Riehle, Marcel; Rief, Winfried; Lincoln, Tania M.

doi:10.1016/j.jpsychires.2023.01.014

Cited by 4 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was preregistered at clinicaltrials.gov (identifier: NCT03863691) and was part of a larger series of studies in which volunteers took 300 mg of Amisulpride or placebo. The other studies' results are presented elsewhere (Berg et al, 2022;Berg et al, 2023). All volunteers underwent medical examination prior to testing.…”

Section: Methodsmentioning

confidence: 99%

Short-term intake of amisulpride does not alter psychobiological stress responses. A randomized, double-blind, placebo-controlled paradigm using a standardized stressor

Berg,

Clamor,

Rief

et al. 2023

Schizophrenia Research

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Short-term intake of amisulpride does not alter psychobiological stress responses. A randomized, double-blind, placebo-controlled paradigm using a standardized stressor

Berg,

Clamor,

Rief

et al. 2023

Schizophrenia Research

Self Cite

View full text Add to dashboard Cite

A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia

Wu,

Kwan,

Rhee

et al. 2023

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

D’Ávila,

Hall,

Horvath

2024

Endocrinology

View full text Add to dashboard Cite

For centuries, increasingly sophisticated methods and approaches have been brought to bear to promote weight loss. Second, only to the Holy Grail of research on aging, the idea of finding a single and simple way to lose weight has long preoccupied the minds of layman. and scientists alike. The effects of obesity are far-reaching and not to be minimized; the need for more effective treatments is obvious. Is there a single silver bullet that addresses this issue without effort on the part of the individual? The answer to this question has been one of the most elusive and sought-after in modern history. Now and then, a miraculous discovery propagates the illusion that a simple solution is possible. Now, there are designer drugs that seem to accomplish the task: we can lose weight without effort using mono-, dual-, and triple agonists of receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon. There are, however, fundamental biological principles that raise intriguing questions about these therapies beyond the currently reported side effects. This perspective reflects upon these issues from the angle of complex goal-oriented behaviors, and systemic and cellular metabolism associated with satiety and hunger.

show abstract

Does partial blockade of dopamine D2 receptors with Amisulpride cause anhedonia? An experimental study in healthy volunteers

Cited by 4 publications

References 81 publications

Short-term intake of amisulpride does not alter psychobiological stress responses. A randomized, double-blind, placebo-controlled paradigm using a standardized stressor

Short-term intake of amisulpride does not alter psychobiological stress responses. A randomized, double-blind, placebo-controlled paradigm using a standardized stressor

A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

Contact Info

Product

Resources

About